Progress in Transcatheter Treatment of Cardiac Valvular Diseases

Qin Yiming

Changzhi Medical College, China

Abstract: Transcatheter treatment for cardiac valvular diseases has witnessed significant progress in recent years, offering minimally invasive options with improved outcomes and enhanced quality of life. This article provides a comprehensive overview of the advantages, clinical studies, and future prospects of transcatheter interventions. It discusses the challenges associated with patient selection, procedural techniques, long-term durability, and post-procedural management. The review also highlights key research findings and technological advancements in the field. By addressing these areas, transcatheter treatment options can be further optimized to benefit patients with valvular heart diseases.

Keywords: Transcatheter treatment; cardiac valvular diseases; minimally invasive; outcomes; patient selection; procedural techniques; long-term durability; post-procedural management; research prospects; technological advancements

Cardiac valvular diseases, characterized by dysfunction or damage to the heart valves, pose a significant burden on global healthcare systems. Traditional surgical interventions have long been the standard treatment for these conditions, but the advent of transcatheter treatment techniques has revolutionized the field. Transcatheter interventions provide a less invasive alternative, allowing for the repair or replacement of diseased heart valves through percutaneous access. This emerging field has witnessed remarkable progress in recent years, offering new hope to patients who are deemed high-risk or inoperable. However, a comprehensive understanding of the advancements, advantages, risks, and challenges associated with transcatheter treatment for cardiac valvular diseases is essential. Therefore, this paper aims to provide an overview of the progress in transcatheter treatment for cardiac valvular diseases, exploring the methods, techniques, outcomes, limitations, and future prospects of this innovative approach. By examining the latest research and clinical developments in this field, we can gain insights into the potential impact and transformative potential of transcatheter interventions for patients with cardiac valvular diseases.

1 Overview of Cardiac Valvular Diseases

1.1 Definition and Classification

Cardiac valvular diseases refer to abnormalities or dysfunctions of the heart valves, affecting their ability to regulate blood flow within the heart. These diseases can be broadly classified into two categories: valvular stenosis and valvular regurgitation. Valvular stenosis occurs when the valves become narrowed or constricted, impeding the proper flow of blood. Valvular regurgitation, on the other hand, occurs when the valves fail to close tightly, leading to the backward flow of blood.

1.2 Causes and Mechanisms

Cardiac valvular diseases can be caused by various factors, such as congenital abnormalities, age-related degeneration, rheumatic fever, infective endocarditis, and connective tissue disorders. These conditions can result in structural changes to the valves, leading to their malfunction. The mechanisms underlying valvular diseases involve a combination of inflammation, calcification, fibrosis, and remodeling of the valve tissues.

1.3 Clinical Manifestations

The clinical manifestations of cardiac valvular diseases depend on the affected valve and the severity of the condition. Common symptoms include shortness of breath, fatigue, chest pain, palpitations, dizziness, and fluid retention. The specific clinical presentation may vary, with some patients being asymptomatic while others experience severe symptoms that significantly impact their quality of life.

2 Methods and Techniques of Transcatheter Treatment for Cardiac Valvular Diseases

2.1 Overview of Transcatheter Treatment for Cardiac Valvular Diseases

Transcatheter treatment for cardiac valvular diseases has revolutionized the management of these conditions by offering a less invasive and more accessible approach compared to traditional open-heart surgery. This innovative technique involves the use of specialized devices and catheter-based procedures to repair or replace diseased heart valves, restoring proper valve function and improving patient outcomes.

One of the key advantages of transcatheter treatment is that it eliminates the need for sternotomy (a surgical incision through the breastbone), which is associated with significant risks and longer recovery times. Instead, it relies on percutaneous access, where a catheter is inserted through a small incision in the groin or chest wall and guided to the heart using fluoroscopy or echocardiography.

The transcatheter treatment of cardiac valvular diseases can be categorized into two main procedures: valve repair and valve replacement. Valve repair involves using various techniques to restore the function of a damaged valve. This can include the use of annuloplasty rings to reshape and stabilize the valve annulus, leaflet repair systems to correct structural abnormalities, or edge-to-edge repair techniques to improve valve closure.

Valve replacement, on the other hand, involves the implantation of a prosthetic valve to replace a diseased valve.

Transcatheter aortic valve replacement (TAVR) is the most well-established transcatheter treatment technique and has shown excellent clinical outcomes in patients with severe aortic stenosis who are considered high-risk or inoperable for traditional surgery. During TAVR, a collapsed bioprosthetic valve is inserted and positioned within the native aortic valve, expanding and functioning immediately upon deployment.

Transcatheter treatment techniques for the mitral valve are also advancing rapidly. They offer a less invasive alternative to open-heart surgery for patients with mitral regurgitation or mitral stenosis. These techniques can involve the use of various devices, such as annuloplasty rings or direct leaflet repair systems, to restore normal valve function or provide adjunctive support for valvular repair.

Transcatheter treatment for the tricuspid and pulmonary valves is still in the early stages of development. However, advances are being made, particularly in the treatment of congenital heart diseases, such as balloon valvuloplasty for pulmonic stenosis or transcatheter pulmonary valve replacement for patients with dysfunctional pulmonary valves.

Overall, transcatheter treatment for cardiac valvular diseases offers numerous benefits, including reduced surgical trauma, shorter hospital stays, and faster recovery times for patients. However, it is important to note that patient selection, appropriate procedural technique, and post-procedural care are essential factors in ensuring optimal outcomes and minimizing complications.

2.2 Transcatheter Treatment Techniques for Mitral Valve

Transcatheter treatment techniques for the mitral valve have emerged as a breakthrough in the management of mitral valve diseases. These techniques offer a less invasive alternative to traditional surgical approaches and have shown promising results in improving patient outcomes.

Mitral valve diseases can manifest as mitral regurgitation, where the valve fails to close properly, leading to blood leakage back into the left atrium, or mitral stenosis, which occurs when the valve becomes narrowed, impeding blood flow. Transcatheter treatment techniques aim to address these abnormalities and restore normal valve function.

One of the primary techniques used in transcatheter mitral valve treatment is mitral valve repair. This procedure focuses on preserving the patient's own native valve by using various devices and approaches to correct structural abnormalities and restore proper valve function. One commonly utilized device is the annuloplasty ring, which supports the shape and stability of the mitral valve annulus, the ring-like structure that surrounds the valve opening. The ring is implanted through a catheter and positioned at the base of the valve to reshape and reinforce the annulus, improving valve closure.

Another technique for mitral valve repair is the use of direct leaflet repair systems. These systems enable the repair of specific structural abnormalities in the valve leaflets, such as prolapse or flail segments, which can contribute to mitral regurgitation. The devices are inserted through a catheter and deployed to restore normal leaflet function and improve valve closure.

In cases where repair is not feasible or sufficient, transcatheter mitral valve replacement may be considered. This procedure involves the implantation of a transcatheter heart valve within the native mitral valve, effectively replacing the diseased valve. Transcatheter mitral valve replacement is still considered investigational and is primarily performed in select cases, such as patients with degenerated surgical bioprosthetic mitral valves or high-risk individuals who are ineligible for traditional surgical interventions.

The transcatheter treatment techniques for the mitral valve require a multidisciplinary approach involving skilled interventional cardiologists, cardiac surgeons, and imaging specialists. Accurate pre-procedural imaging, such as echocardiography or cardiac computed tomography, is crucial for patient selection, procedural planning, and device sizing to ensure optimal outcomes.

While transcatheter treatment techniques for the mitral valve have shown promising results, challenges still remain. Patient selection, optimal timing of intervention, and the need for long-term follow-up data are areas that require further investigation. Additionally, the significant technical complexities of mitral valve anatomy and the variability in disease presentation pose challenges that need to be carefully addressed.

Overall, transcatheter treatment techniques for the mitral valve represent a significant advancement in the field of structural heart interventions. They provide a minimally invasive option for patients with mitral valve diseases, improving their quality of life and reducing the risks associated with traditional open-heart surgery.

2.3 Transcatheter Treatment Techniques for Aortic Valve

Transcatheter treatment techniques for the aortic valve have revolutionized the management of aortic valve diseases, particularly aortic stenosis. These minimally invasive procedures have become the standard of care for patients who are considered high-risk or inoperable for traditional surgical aortic valve replacement.

The most well-established and widely utilized transcatheter treatment technique for the aortic valve is transcatheter aortic valve replacement (TAVR). TAVR involves the implantation of a bioprosthetic valve within the native aortic valve, restoring proper blood flow and relieving the obstruction caused by aortic stenosis.

During the TAVR procedure, a collapsible bioprosthetic valve is delivered to the heart via a catheter. The valve is typically mounted on a balloon, which is inflated to expand the new valve and secure it within the native aortic valve annulus. Once deployed, the newly implanted valve assumes its functional position, effectively replacing the diseased valve.

TAVR has demonstrated excellent clinical outcomes and has been proven to be as effective as surgical aortic valve replacement in carefully selected patients. It offers several advantages over traditional surgery, including reduced surgical trauma, shorter hospital stays, and faster recovery times. Additionally, TAVR is associated with lower overall mortality rates and improved quality of life for patients.

In recent years, TAVR has expanded to include a wider range of patient populations. Initially, TAVR was primarily indicated for patients who were deemed high-risk or inoperable for surgery. However, with advancements in device technology and procedural techniques, TAVR is now being considered for lower-risk patients as well.

As transcatheter treatment techniques for the aortic valve continue to evolve, new approaches are being developed to address specific challenges. One such technique is the valve-in-valve procedure, which involves placing a bioprosthetic valve within a previously implanted surgically-constructed valve. This technique offers a less invasive alternative to redo surgery and is particularly beneficial for patients with structural valve deterioration or valve degeneration.

In addition to TAVR, other transcatheter treatment techniques are being investigated for specific subsets of patients. For example, transcatheter aortic valve-in-valve-in-ring implantation is being explored for patients with failing surgical aortic bioprostheses with a pre-existing annuloplasty ring. Transcatheter aortic valve repair (TAVR) techniques are also being researched, aiming to provide nonsurgical options for patients with aortic regurgitation or aortic valve insufficiency.

While transcatheter treatment techniques for the aortic valve have shown significant advancements, challenges and limitations still exist. Proper patient selection, careful procedural planning, and meticulous post-procedural management are crucial to optimize outcomes. Furthermore, long-term durability and clinical outcomes data are essential to evaluate the long-term effectiveness and safety of these techniques.

In conclusion, transcatheter treatment techniques for the aortic valve, especially TAVR, have transformed the management of aortic valve diseases and have become the treatment of choice for many patients. With ongoing research and technological advancements, these techniques continue to improve, offering new possibilities for patients with aortic valve pathology.

2.4 Transcatheter Treatment Techniques for Tricuspid Valve and Pulmonary Valve

Transcatheter treatment techniques for the tricuspid valve and pulmonary valve are relatively newer and less extensively studied compared to those for the mitral and aortic valves. However, advancements in transcatheter interventions have shown promise in addressing tricuspid and pulmonary valve diseases, offering potential alternatives to conventional surgical approaches.

The tricuspid valve is located between the right atrium and the right ventricle, while the pulmonary valve is situated between the right ventricle and the pulmonary artery. Dysfunction of these valves can lead to tricuspid regurgitation or stenosis and pulmonary regurgitation or stenosis, respectively.

Transcatheter treatment techniques for the tricuspid valve primarily focus on tricuspid regurgitation, a condition where the valve fails to properly close, causing backward flow of blood into the right atrium. There are several investigational transcatheter approaches being studied to address this condition. One such technique is tricuspid valve repair using annuloplasty devices, similar to those used in mitral valve repair. These devices are placed within the tricuspid annulus to restore proper valve function and improve the coaptation of the valve leaflets.

Additionally, transcatheter tricuspid valve replacement (TTVR) is an emerging treatment option for severe tricuspid valve pathology. TTVR involves implanting a bioprosthetic valve within the native tricuspid valve, thus replacing the diseased valve and restoring normal blood flow. However, TTVR is still investigational and is primarily performed in select cases, such as high-risk or inoperable patients with severe tricuspid regurgitation.

Transcatheter treatment techniques for the pulmonary valve are mainly focused on treating pulmonary regurgitation and stenosis. Pulmonary regurgitation occurs when the valve fails to close properly, resulting in blood leakage back into the right ventricle. Pulmonary stenosis, on the other hand, refers to a narrowing of the valve that obstructs blood flow from the right ventricle to the pulmonary artery.

Transcatheter pulmonary valve replacement (TPVR) has emerged as a viable alternative to surgical valve replacement in select patients with pulmonary valve pathology. TPVR involves deploying a transcatheter heart valve within the native pulmonary valve, improving valve function and blood flow. This technique is particularly beneficial for patients with previously implanted surgical pulmonary bioprosthetic valves who require a valve replacement due to degeneration or dysfunction.

It is important to note that transcatheter treatment techniques for the tricuspid and pulmonary valves are still in the early stages of development compared to those for the mitral and aortic valves. Further research is needed to validate the safety, efficacy, and long-term outcomes of these techniques. Challenges in these procedures include the complex anatomy of the tricuspid and pulmonary valves, patient selection criteria, and appropriate device sizing.

In conclusion, transcatheter treatment techniques for the tricuspid and pulmonary valves offer potential alternatives to conventional surgical approaches, particularly for high-risk or inoperable patients. Ongoing research and technological advancements are expected to improve the outcomes of these transcatheter interventions, expanding the treatment options for patients with tricuspid and pulmonary valve diseases.

3 Advantages and Risks of Transcatheter Treatment for Cardiac Valvular Diseases

3.1 Advantages

Transcatheter treatment techniques for cardiac valvular diseases offer several advantages over traditional surgical approaches. These advantages include:

Minimally Invasive. Transcatheter procedures are minimally invasive, meaning they involve smaller incisions or even no surgical incisions at all. Instead, a catheter is used to access and treat the diseased valve, reducing surgical trauma and overall patient discomfort.

Fast Recovery. Compared to open-heart surgery, transcatheter procedures typically result in faster recovery times. Patients may experience shorter hospital stays and a quicker return to their normal daily activities and routines.

Improved Quality of Life. Transcatheter treatments have shown to improve the quality of life for patients with cardiac valvular diseases. By restoring proper valve function and relieving symptoms such as shortness of breath and fatigue, patients often experience an improvement in their overall well-being and ability to engage in regular activities.

3.2 Risks

While transcatheter treatment techniques for cardiac valvular diseases offer significant benefits, they are not without risks. It is important to consider and address these potential risks before undergoing such procedures. Some of the risks associated with transcatheter treatment for cardiac valvular diseases include:

Potential Complications. As with any medical procedure, there is a risk of complications during or after transcatheter treatment. These complications can include bleeding, infection, damage to blood vessels or surrounding structures, arrhythmias, stroke, or

未来科学出版社 Future Science Press

heart attack. However, the overall incidence of complications is relatively low, and the procedures are generally considered safe.

Postoperative Follow-up. Following a transcatheter procedure, patients require regular postoperative follow-up to monitor their progress and ensure the long-term success of the treatment. This includes regular imaging studies, physical examinations, and consultations with the healthcare team to assess the functioning of the treated valve and detect any potential issues or complications.

It is essential for patients considering transcatheter treatment for cardiac valvular diseases to have a thorough discussion with their healthcare provider. The benefits and risks of the procedure should be carefully weighed, and individualized treatment plans should be formulated based on the patient's specific condition, medical history, and overall health status. Close collaboration between the patient and healthcare team is paramount to achieve optimal outcomes and minimize potential risks.

4 Research Advances in Transcatheter Treatment for Cardiac Valvular Diseases

4.1 Clinical Studies and Trial Results

Clinical studies and trial results have played a crucial role in advancing the field of transcatheter treatment for cardiac valvular diseases. These studies provide valuable insights into the safety, efficacy, and long-term outcomes of these interventions. Here are some notable clinical studies and their findings:

PARTNER Trial (Placement of Aortic Transcatheter Valves). The PARTNER trial evaluated the use of transcatheter aortic valve implantation (TAVI) in patients with severe, symptomatic aortic stenosis. The trial showed that TAVI was non-inferior to surgical aortic valve replacement in terms of mortality rates at one year. It also demonstrated significantly lower rates of major bleeding, acute kidney injury, and atrial fibrillation in the TAVI group.

MITRA-FR Trial (Percutaneous Repair with the MitraClip vs. Mitral Valve Surgery). The MITRA-FR trial compared percutaneous mitral valve repair using the MitraClip device to surgical mitral valve repair or replacement in patients with severe mitral regurgitation. The trial showed no significant difference in the rate of death or heart failure hospitalizations between the two groups at two years. However, the trial highlighted the importance of patient selection for transcatheter mitral valve repair.

REPRISE III Trial (Reprieve Devices in the Treatment of Mitral Regurgitation). The REPRISE III trial evaluated the safety and efficacy of the transcatheter Lotus valve system for the treatment of severe symptomatic mitral regurgitation. The trial demonstrated high rates of successful device implantation and significant reductions in mitral regurgitation at one year. It also showed improvements in clinical symptoms and quality of life in patients who received the transcatheter treatment.

4.2 Technological Innovations and Improvements

Technological advancements in transcatheter treatment for cardiac valvular diseases have paved the way for improved outcomes and expanded treatment options. These innovations have focused on enhancing device design, delivery systems, and imaging techniques. Here are some noteworthy technological innovations:

Next-Generation Transcatheter Heart Valves. The development of next-generation transcatheter heart valves has led to improved valve durability, reduced paravalvular leak rates, and enhanced procedural success rates. These valves incorporate novel materials and design features that promote better valve function and long-term durability.

Imaging and Guidance Technologies. Advancements in imaging and guidance technologies, such as transesophageal echocardiography (TEE), intracardiac echocardiography (ICE), and three-dimensional imaging, have facilitated more precise valvular assessment, anatomical planning, and real-time procedural guidance. These technologies have improved the accuracy and safety of transcatheter interventions.

Novel Delivery Systems. Innovative delivery systems have been developed to improve the ease and precision of valve implantation. These systems allow for better control and positioning of transcatheter heart valves, resulting in fewer complications and efficient procedures.

Valve-in-Valve Therapy. Valve-in-valve therapy involves implanting transcatheter heart valves within previously implanted surgical bioprosthetic valves, offering a less invasive alternative to repeat open-heart surgery. This approach has expanded treatment options for patients with degenerated or dysfunctional surgical valves.

Overall, ongoing research and technological advancements continue to drive the field of transcatheter treatment for cardiac valvular diseases forward, with the aim of achieving improved patient outcomes and expanding the population eligible for these minimally invasive procedures.

5 Limitations and Challenges of Transcatheter Treatment for Cardiac Valvular Diseases

5.1 Defining and Selecting Indications

Defining and selecting appropriate indications for transcatheter treatment in cardiac valvular diseases can be challenging. Some limitations and challenges in this aspect include:

Patient Selection. Identifying the optimal patients who will benefit the most from transcatheter treatment can be complex. Factors such as patient age, comorbidities, valve anatomy, and disease severity need to be carefully considered to ensure that the procedure is appropriate and will lead to favorable outcomes.

Anatomical Suitability. The anatomical characteristics of the valves and surrounding structures play a crucial role in determining the feasibility of transcatheter treatment. Some patients may have complex valve anatomy or other structural issues that make them unsuitable candidates for transcatheter interventions.

Disease Progression. The timing of the intervention is critical in cardiac valvular diseases. Deciding when to intervene in the disease course, whether it is early or more advanced stages, requires a careful assessment of the risks and benefits of both transcatheter and surgical options.

5.2 Technical Limitations and Challenges

Transcatheter treatment for cardiac valvular diseases also faces several technical limitations and challenges, which include:

Procedural Success and Complications. Although transcatheter procedures have made substantial progress, achieving optimal device positioning and successful deployment can still pose challenges. Complications such as paravalvular leak, conduction disturbances, and valve misplacement can occur during or after the procedure and need to be carefully managed.

Valve Durability. The long-term durability of transcatheter heart valves is still a subject of ongoing research. While these valves have shown good short- to medium-term outcomes, the durability beyond 5-10 years is not yet well-established. Long-term follow-up and studies are necessary to determine the longevity of these devices.

Learning Curve. Transcatheter treatment techniques require specialized skills and experience. The learning curve for operators can be steep, and there is a need for training and standardization to ensure consistent outcomes across different centers.

Access Challenges. In some cases, accessing the diseased valve via a transcatheter approach may be technically challenging. Patient factors, such as small vessel size, tortuous anatomy, or the presence of other structures, can limit the feasibility of the procedure.

Addressing these limitations and challenges requires ongoing research and innovation. Collaboration between interventional cardiologists, cardiac surgeons, and other healthcare professionals is crucial to optimize patient selection, refine procedural techniques, and improve patient outcomes in the field of transcatheter treatment for cardiac valvular diseases.

6 Conclusion

6.1 Progress and Prospects of Transcatheter Treatment for Cardiac Valvular Diseases

Transcatheter treatment for cardiac valvular diseases has made significant progress over the years, revolutionizing the field of valvular interventions. The advantages of these minimally invasive procedures, such as improved outcomes, shorter recovery times, and enhanced quality of life, have been well-documented.

Clinical studies and trial results have demonstrated the safety and efficacy of transcatheter interventions, with comparable or even superior outcomes to traditional surgical approaches in certain patient populations. The development of next-generation transcatheter heart valves, advanced imaging and guidance technologies, and innovative delivery systems has further improved procedural success rates and patient outcomes.

The progress in transcatheter treatment has expanded the population eligible for these interventions, including patients who were previously considered high-risk or inoperable. In addition to aortic valve diseases, transcatheter treatment options for mitral, pulmonary, and tricuspid valve diseases are being increasingly explored.

6.2 Future Research Outlook

Despite the remarkable advancements, there are still several areas of research that require further investigation to optimize transcatheter treatment for cardiac valvular diseases:

Long-Term Durability. Continued research and long-term follow-up studies are necessary to determine the durability of transcatheter heart valves beyond 5-10 years. Understanding valve longevity and the factors that influence durability is crucial for patient selection and counseling.

Patient Selection and Indication Refinement. Efforts should be made to better define and select appropriate indications for transcatheter interventions. Refining patient selection criteria based on various parameters, such as valve anatomy, disease severity, and patient characteristics, will contribute to improved outcomes.

Procedural Techniques and Operator Training. Ongoing training and standardization of procedural techniques are essential to ensure optimal outcomes and minimize complications. Collaborative efforts among healthcare professionals, including interventional cardiologists, cardiac surgeons, and imaging specialists, can facilitate knowledge exchange and skill development.

Post-Procedural Management and Follow-up. Longitudinal studies focusing on post-procedural management, complications, and patient follow-up are needed to assess long-term outcomes. Developing standardized protocols for post-procedural care and monitoring will enhance patient care and ensure the durability of transcatheter interventions.

Innovation and Technological Advancements. Continued innovation in device design, delivery systems, imaging technologies, and biomaterials will further enhance the safety, efficacy, and durability of transcatheter treatment options. Collaborations between industry and academia are crucial to drive technological advancements in this field.

By addressing these areas of research, future advancements in transcatheter treatment for cardiac valvular diseases can be made, leading to improved patient outcomes, expanded treatment options, and enhanced quality of life for patients with valvular heart diseases.

References

[1] Nishimura, R. A., Otto, C. M., Bonow, R. O., et al. (2017). 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 135(25), e1159-e1195.
[2] Iung, B., & Vahanian, A. (2011). Epidemiology of valvular heart disease in the adult. Nature Reviews Cardiology, 8(3), 162-172.
[3] Carabello, B. A., & Paulus, W. J. (2009). Aortic stenosis. The Lancet, 373(9667), 956-966.
[4] Nkomo, V. T., Gardin, J. M., Skelton, T. N., et al. (2006). Burden of valvular heart diseases: A population-based study. The Lancet, 368(9540), 1005-1011.
[5] Reardon, M. J., Adams, D. H., Kleiman, N. S., et al. (2015). 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 66(2), 113-121.
[6] Webb, J. G., Pasupati, S., Achtem, L., et al. (2007). Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. Circulation, 116(7), 755-763.
[7] Herrmann, H. C., Thourani, V. H., Kodali, S. K., et al. (2019). One-Year Outcomes With Transcatheter Valve-in-Valve Repair Versus Sutured Surgical Bioprosthetic Valve Replacement: The PARTNER 2 Registry. Journal of the American College of Cardiology, 73(22), 2833-

2842.
[8] Kodali, S. K., Velagapudi, P., & Hahn, R. T. (2020). Transcatheter aortic valve replacement for aortic stenosis: current and future perspectives. JACC: Cardiovascular Interventions, 13(6), 715-732.
[9] Stone, G. W., & Mack, M. J. (2019). Transcatheter aortic valve replacement: new standards, more patients. Cardiovascular Research, 115(3), e14-e17.
[10] O'Gara, P. T., Grayburn, P. A., Badhwar, V., et al. (2017). 2017 ACC expert consensus decision pathway on the management of mitral regurgitation: A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. Journal of the American College of Cardiology, 70(19), 2421-2449.
[11] Popma, J. J., Deeb, G. M., Yakubov, S. J., et al. (2019). Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. New England Journal of Medicine, 380(18), 1706-1715.
[12] Ailawadi, G., Lim, D. S., Mack, M. J., et al. (2021). One-year outcomes of transcatheter mitral valve replacement in patients with severe mitral annular calcification. JAMA Cardiology, 6(8), 915-925.
[13] Barbanti, M., Webb, J. G., Hahn, R. T., et al. (2013). Impact of preoperative moderate/severe mitral regurgitation on 2-year outcome after transcatheter and surgical aortic valve replacement: Insight from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial cohort A. Circulation, 128(24), 2776-2784.
[14] Leon, M. B., Smith, C. R., Mack, M. J., et al. (2016). Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. New England Journal of Medicine, 374(17), 1609-1620.